Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Gossamer Bio (GOSS) Research & Development (2022 - 2025)

Historic Research & Development for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $45.5 million.

  • Gossamer Bio's Research & Development rose 3050.41% to $45.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.3 million, marking a year-over-year increase of 2185.58%. This contributed to the annual value of $138.5 million for FY2024, which is 235.25% up from last year.
  • Per Gossamer Bio's latest filing, its Research & Development stood at $45.5 million for Q3 2025, which was up 3050.41% from $41.6 million recorded in Q2 2025.
  • Gossamer Bio's 5-year Research & Development high stood at $45.5 million for Q3 2025, and its period low was $30.0 million during Q4 2023.
  • Moreover, its 4-year median value for Research & Development was $37.8 million (2023), whereas its average is $38.0 million.
  • As far as peak fluctuations go, Gossamer Bio's Research & Development crashed by 2990.18% in 2023, and later soared by 3050.41% in 2025.
  • Over the past 4 years, Gossamer Bio's Research & Development (Quarter) stood at $41.5 million in 2022, then dropped by 27.8% to $30.0 million in 2023, then grew by 20.49% to $36.1 million in 2024, then grew by 26.11% to $45.5 million in 2025.
  • Its Research & Development was $45.5 million in Q3 2025, compared to $41.6 million in Q2 2025 and $38.0 million in Q1 2025.